Portage Biotech (Portage Biotech) Debt-to-Asset : 0.01 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Portage Biotech Debt-to-Asset?

Portage Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.05 Mil. Portage Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.23 Mil. Portage Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $49.04 Mil. Portage Biotech's debt to asset for the quarter that ended in Dec. 2023 was 0.01.

Portage Biotech Debt-to-Asset Historical Data

The historical data trend for Portage Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech Debt-to-Asset Chart

Portage Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.01

Portage Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	0.01

Competitive Comparison of Portage Biotech's Debt-to-Asset

For the Biotechnology subindustry, Portage Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Portage Biotech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Portage Biotech's Debt-to-Asset falls into.

Portage Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Portage Biotech's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	99.129
	=	0.00

Portage Biotech's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.05	+	0.225)	/	49.035
	=	0.01

Portage Biotech (NAS:PRTG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Portage Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Portage Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Portage Biotech (Portage Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110

Website

https://www.portagebiotech.com

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.